Healthcare >> CEO Interviews >> September 29, 2003
JOHN W. FARA joined Depomed, Inc., as a Director in November 1995 and as
its President and Chief Executive Officer in December 1996. In March
2000 he was elected Chairman. Between 1990 and 1996 he was with Anergen,
Inc., a biotechnology company, as President and Chief Executive Officer.
Prior to his tenure at Anergen he was President of Prototeck, Inc., a
biotechnology company, and during the previous 10 years was at ALZA
Corp. where he held the positions of Director of Biomedical Research and
then Vice President of Business Development. Dr. Fara also serves as a
Director of AVI Biopharma and IOMED, Inc., publicly traded
pharmaceutical companies. He received a BS from the University of
Wisconsin, Madison, and a PhD from the University of California, Los
Angeles. Profile
TWST: Could you explain the technology used by Depomed as well as theproducts you are developing with this technology?
Dr. Fara: We have an oral drug delivery tablet technology called